SIGN UP

SIGN UP TO LEARN MORE

Largely unaddressed inflammation and fibrosis may be damaging your patients' kidneys. However, new discoveries about chronic kidney disease and type 2 diabetes are well underway.1-6

Sign up below for updates on CKD and T2D, inflammation and fibrosis, and news from Bayer.

Do you have a medical scientific question regarding our nephrology portfolio? Our medical scientific experts are here to support you in your daily clinical practice! Request an online appointment.
Click here
Hear from your peers about inflammation and fibrosis in CKD progression2,7
Watch here

CKD: chronic kidney disease; T2D: type 2 diabetes.

References:

  • Tesch GH, et al. Front Pharmacol. 2017;8. doi:10.3389/fphar.2017.00313. Return to content
  • Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. Return to content
  • Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181–191. Return to content
  • Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1–S115. Return to content
  • Cosentino F, et al; ESC Scientific Document Group. Eur Heart J. 2020;41(2):255–323. Return to content
  • Tuttle KR, et al. Am J Kidney Dis. 2021;77(1):94–109. Return to content
  • Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10.1155/2015/697010. Return to content